IMMX Insider Trading (Immix Biopharma)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $550.00
Immix Biopharma Share Price & Price History
Current Price: $2.45
Price Change: ▼ Price Decrease of -0.01 (-0.41%)
As of 08/12/2022 01:00 AM ET
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Immix Biopharma Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/14/2022||Sean Senn||Major Shareholder||Sell||200||$2.75||$550.00||899,800|| |
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
Immix Biopharma Institutional Trading History
Data available starting January 2016
|Reporting Date||Hedge Fund||Shares Held||Market Value||% of Portfolio||Quarterly Change in Shares||Ownership in Company||Details|
|5/17/2022||Virtu Financial LLC||23,515||$57K||0.0%||N/A||0.170%|
|5/13/2022||Renaissance Technologies LLC||62,600||$0.15M||0.0%||N/A||0.452%|
|5/13/2022||XTX Topco Ltd||12,992||$31K||0.0%||N/A||0.094%|
|5/11/2022||InterOcean Capital Group LLC||15,900||$38K||0.0%||N/A||0.115%|
|2/14/2022||Altium Capital Management LP||122,388||$0.44M||0.1%||N/A||1.616%|
|2/9/2022||Context Capital Management LLC||11,532||$41K||0.0%||N/A||0.152%|
|2/2/2022||PVG Asset Management Corp||20,000||$71K||0.3%||N/A||0.264%|
|2/1/2022||Eidelman Virant Capital||29,856||$0.10M||0.0%||N/A||0.394%|
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Immix Biopharma?